What is Roth Capital’s Forecast for Cingulate Q1 Earnings?

Cingulate Inc. (NASDAQ:CING) – Roth Capital issued their Q1 2026 earnings per share estimates for shares of Cingulate in a note issued to investors on Monday, March 31st. Roth Capital analyst B. Pachaiyappan anticipates that the company will earn ($0.48) per share for the quarter. Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Roth Capital also issued estimates for Cingulate’s Q2 2026 earnings at ($0.57) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.76) EPS.

Several other research analysts also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Cingulate in a research note on Thursday, March 6th. Roth Mkm initiated coverage on shares of Cingulate in a research note on Friday, January 10th. They set a “buy” rating and a $12.00 price objective on the stock.

Cingulate Stock Down 1.1 %

NASDAQ CING opened at $4.30 on Tuesday. The stock has a market cap of $13.81 million, a price-to-earnings ratio of -0.29 and a beta of -0.83. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The business has a fifty day moving average of $4.27 and a 200-day moving average of $4.44.

Institutional Investors Weigh In On Cingulate

Several hedge funds have recently modified their holdings of CING. Geode Capital Management LLC acquired a new stake in shares of Cingulate during the 4th quarter worth $135,000. Commonwealth Equity Services LLC increased its stake in Cingulate by 281.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 43,022 shares of the company’s stock worth $212,000 after acquiring an additional 31,746 shares during the last quarter. AlphaMark Advisors LLC raised its holdings in shares of Cingulate by 50,000.0% in the 4th quarter. AlphaMark Advisors LLC now owns 5,010 shares of the company’s stock worth $25,000 after purchasing an additional 5,000 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of Cingulate in the 3rd quarter valued at about $106,000. 41.31% of the stock is owned by institutional investors and hedge funds.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.